Wuhan BinSheng Bio-Technology

Binsheng Bio is a clinical-stage biotechnology company based in Wuhan, China, specializing in the development of next-generation oncolytic virus therapies for cancer treatment. The company's core technology platform focuses on genetically engineered Herpes Simplex Virus type 1 (HSV-1) to selectively infect and lyse tumor cells while stimulating a systemic anti-tumor immune response. Its lead candidate, BS001 (OH2), is currently undergoing clinical trials for various solid tumors, including melanoma and liver cancer. Binsheng Bio aims to provide innovative and effective immunotherapy solutions to address unmet medical needs in oncology through its proprietary viral engineering expertise.